The effect of thalidomide on tissue factor activity in Mono Mac 6 cells and the relationship to tumor necrosis factor (TNF)-α-stimulated cells

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 12, 2003, Pages 2691-2692

  Arkel, Y S ^a   Ku, D H W ^a   Thurston, A L ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THALIDOMIDE; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA;

BIOSYNTHESIS; CELL LINE; DRUG EFFECT; HUMAN; LETTER; METABOLISM; MONOCYTE;

CELL LINE; HUMANS; MONOCYTES; THALIDOMIDE; THROMBOPLASTIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 1542440155     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2003.0543i.x     Document Type: Letter

References (12)

1. Klausner JD, Makonkawkeyoon S, Akarasewi P, Nakata K, Kasinrerk W, Corral L, Dewar RL, Lane HC, Freedman VH, Kaplan G. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. JAcquir Immune Defic SyndrHum Retrovirol 1996; 11: 247-57.
2. Stevens RJ, Andujar C, Edwards CJ, Ames PR, Barwick AR, Khamashta MA, Hughes GR. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients. Br J Rheumatol 1997; 36: 353-9.
3. Wesh O, Gomez M, Mancias C, Ibarra Leal S, Millikan LE. A new therapeutic approach to type II leprosy reaction. Int J Dermatol 1999; 38: 931-3.
4. Barbui T, Falanga A. Thalidomide and thrombosis in multiple myeloma. J Thromb Haemost 2003; 1: 421-2.
5. Bowcock SJ, Rassam SM, Ward SM, Turner JT, Laffan M. Thromboembolism in patients on thalidomide for myeloma. Hematology 2002; 7: 51-3.
6. Steurer M, Sudmeier I, Stauder R, Gastl G. Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha. Br J Haematol 2003; 121: 101-3.
7. Bennett CL, Schumock GT, Desai AA, Kwaan HC, Raisch DW, Newlin R, Stadler W. Thalidomide-associated deep vein thrombosis and pulmonary embolism. Am J Med 2002; 113: 603-6.
8. Cavo M, Zamagni E, Cellini C, Tosi P, Gangini D, Cini M, Valdre L, Palareti G, Masini L, Tura S, Baccarani M. Deep-vein thrombosis in patients with multiple myeloma receiving irst-line thalidomide-dex-amethasone therapy. Blood 2002; 100: 2272-3.
9. Calabrese L, Fleischer AB. Thalidomide: current and potential clinical applications. Am J Med 2000; 108: 487-95.
10. Drexler HG, Dirks W, MacLeod RAF, Quentmeier H, Steube K, Uphoff CC. DSMZ Catalogue of Human and Animal Cell Lines, 7th edn. Braunschweig: 1999.
11. Muhlfelder TW, Teodorescu V, Rand J, Rosman A, Niemetz J. Human atheromatous plaque extracts induce tissue factor activity (TFA) in monocytes and also express constitutive TFA. Thromb Haemost 1999; 81: 146-50.
12. Corral LG, Muller GW, Moreira AL, Chen Y, Wu M, Stirling D, Kaplan G. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor α inhibitory activity. Mol Med 1996; 2: 506-15.